Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19 (US)

NCT04906694 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

97

Enrollment

INDUSTRY

Sponsor class

Conditions

Covid19

Interventions

BIOLOGICAL: COVI-DROPS
DRUG: Placebo

Sponsor

Sorrento Therapeutics, Inc.